X
[{"orgOrder":0,"company":"Pharmakea therapeutics","sponsor":"Galecto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galecto to merge with onetime Celgene partner PharmAkea","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Pharmakea therapeutics
Filters
Companies By Therapeutic Area
Details:
The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
PAT-1251
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: PAT-1251
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
Galecto
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
January 07, 2020